Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on October 23, 2003, to report its financial results for the third quarter of 2003. The filing primarily incorporates by reference a press release (Exhibit 99.1) detailing these financial results, along with supplemental information (Exhibit 99.2) not contained within the press release. Investors seeking to understand BMY's performance during the third quarter of 2003 should refer to the attached exhibits for detailed financial figures, including revenue, earnings per share, and any key operational developments or guidance provided by the company. The 8-K serves as the official notification and makes these financial disclosures readily accessible.
Key Highlights
- 1BMY filed an 8-K on October 23, 2003, reporting Q3 2003 financial results.
- 2The primary disclosure is via a press release (Exhibit 99.1) dated October 23, 2003.
- 3Supplemental financial information not included in the press release is also provided as Exhibit 99.2.
- 4The filing is made under Regulation FD and reports on results of operations and financial condition.
- 5Investors can access detailed Q3 2003 financial performance through the incorporated exhibits.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Bristol-Myers Squibb Company's financial results for the third quarter of 2003 and to make these results and related information publicly available under Regulation FD.
The detailed financial results for Q3 2003 are primarily contained within the press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) that are incorporated by reference into this 8-K filing.
This 8-K filing itself does not contain the specific financial numbers. However, it directs investors to Exhibit 99.1 (the press release) and Exhibit 99.2 (supplemental information) where these detailed figures are expected to be presented.